Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ABNORMAL PLASMINOGEN-PLASMIN SYSTEM ACTIVITY (FIBRINOLYSIS) IN PATIENTS WITH HEPATIC CIRRHOSIS: ITS CAUSE AND CONSEQUENCES.

× No keyword cloud information.

31 in total

1. Fibrinolytic mechanisms and the development of thrombolytic therapy.

Authors: A P FLETCHER; N ALKJAERSIG; S SHERRY
Journal: Am J Med Date: 1962-11 Impact factor: 4.965

2. Measurement of extrahepatic shunted blood flow in liver cirrhosis.

Authors: T NAKAMURA; S NAKAMURA; T KANEKO; T SUZUKI; K TOKITA; S ABE
Journal: J Lab Clin Med Date: 1962-12

3. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. III. Demonstration of abnormal clot structure by electron microscopy.

Authors: N U BANG; A P FLETCHER; N ALKJAERSIG; S SHERRY
Journal: J Clin Invest Date: 1962-04 Impact factor: 14.808

4. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization.

Authors: N ALKJAERSIG; A P FLETCHER; S SHERRY
Journal: J Clin Invest Date: 1962-04 Impact factor: 14.808

5. Fibrinolysis induced by pressor amines.

Authors: E GENTON; F KERN; K VON KAULLA
Journal: Am J Med Date: 1961-10 Impact factor: 4.965

6. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products.

Authors: A P FLETCHER; N ALKJAERSIG; S SHERRY
Journal: J Clin Invest Date: 1962-04 Impact factor: 14.808

7. Studies on enhanced fibrinolytic activity in man.

Authors: S SHERRY; R I LINDEMEYER; A P FLETCHER; N ALKJAERSIG
Journal: J Clin Invest Date: 1959-05 Impact factor: 14.808

8. Studies on the thrombolytic activity of human plasma.

Authors: W D SAWYER; A P FLETCHER; N ALKJAERSIN; S SHERRY
Journal: J Clin Invest Date: 1960-02 Impact factor: 14.808

9. Generalized excessive oozing in patients undergoing major surgery and receiving multiple blood transfusions.

Authors: M B ZUCKER; M SIEGEL; E E CLIFFTON; J W BELLVILLE; W S HOWLAND; C E GROSSI
Journal: J Lab Clin Med Date: 1957-12

10. Plasma fibrinolytic activity in cirrhosis of the liver.

Authors: H C KWAAN; A J MCFADZEAN; J COOK
Journal: Lancet Date: 1956-01-21 Impact factor: 79.321

36 in total

1. TO-DAY'S DRUGS. FIBRINOLYTIC ENZYMES AND FIBRINOLYTIC INHIBITORS.

Authors: J H HUTCHISON
Journal: Br Med J Date: 1965-03-13

2. STUDIES WITH COMPLAMIN, A NICOTINIC-ACID-THEOPHYLLINE ESTER, AS A FIBRINOLYTIC AGENT.

Authors: G P MCNICOL; A S DOUGLAS
Journal: Br Med J Date: 1965-05-01

3. Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids.

Authors: Andrey A Komissarov; Galina Florova; Ali Azghani; Sophia Karandashova; Anna K Kurdowska; Steven Idell
Journal: Am J Physiol Lung Cell Mol Physiol Date: 2013-08-30 Impact factor: 5.464

4. Dysfibrinogenemia associated with liver disease.

Authors: J E Palascak; J Martinez
Journal: J Clin Invest Date: 1977-07 Impact factor: 14.808

5. Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.

Authors: S Sato; T Higashi; S Ouguchi; N Hino; T Tsuji
Journal: J Gastroenterol Date: 1994-12 Impact factor: 7.527

ABNORMAL PLASMINOGEN-PLASMIN SYSTEM ACTIVITY (FIBRINOLYSIS) IN PATIENTS WITH HEPATIC CIRRHOSIS: ITS CAUSE AND CONSEQUENCES.